Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ: PLRX )

13.49 +0.15 (+1.12%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 345,814
Open 13.34
Bid (Size) 11.00 (1)
Ask (Size) 15.12 (31)
Prev. Close 13.34
Today's Range 13.18 - 13.55
52wk Range 10.22 - 19.62
Shares Outstanding 35,937,937
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-24.89%
-24.89%
1 Month
+0.22%
+0.22%
3 Month
+19.06%
+19.06%
6 Month
+23.53%
+23.53%
1 Year
-27.16%
-27.16%

More News

Read More
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings
Via Benzinga
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
From Pliant Therapeutics, Inc.
Via GlobeNewswire
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
From Pliant Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
Via Benzinga
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.